• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓炎症将雄激素抑制与前列腺癌患者的心血管风险联系起来。

Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.

作者信息

Beitzen-Heineke Antonia, Wise David R, Berger Jeffrey S

机构信息

Department of Medicine, New York University Grossman School of Medicine, 530 First Avenue, Skirball 9R, New York, NY, 10016, USA.

Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Cardiooncology. 2024 Dec 5;10(1):87. doi: 10.1186/s40959-024-00278-2.

DOI:10.1186/s40959-024-00278-2
PMID:39639392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11619638/
Abstract

Androgen deprivation therapy (ADT), a key element of prostate cancer treatment, is associated with increased risk for cardiovascular morbidity and mortality. The underlying mechanisms include adverse metabolic alterations, but further mechanisms are likely. Animal studies suggest increased progression of atherosclerosis in androgen deprived conditions. Based on in vitro studies, lack of androgens may modulate immune cells including monocytes, macrophages, and T-cells towards a pro-inflammatory phenotype and pro-atherogenic function. As a novel aspect, this review summarizes existing data on the effect of androgens and androgen deprivation on platelet activity, which play a major role in inflammation and in the initiation and progression of atherosclerotic lesions. Testosterone modulates platelet aggregation responses which are affected by dose level, source of androgen, and age. Data on the effects of ADT on platelet activity and aggregation are limited and conflicting, as both increased and decreased aggregation responses during ADT have been reported. Gaps in knowledge about the mechanisms leading to increased cardiovascular risk during ADT remain and further research is warranted. Improved understanding of pathogenic pathways linking ADT to cardiovascular risk may help identify clinically useful diagnostic and prognostic biomarkers, and accelerate finding novel therapeutic targets, and thus optimize prostate cancer treatment outcomes.

摘要

雄激素剥夺疗法(ADT)是前列腺癌治疗的关键要素,与心血管疾病发病率和死亡率增加相关。其潜在机制包括不良代谢改变,但可能还存在其他机制。动物研究表明,在雄激素缺乏的情况下动脉粥样硬化进展加快。基于体外研究,雄激素缺乏可能使包括单核细胞、巨噬细胞和T细胞在内的免疫细胞向促炎表型和促动脉粥样硬化功能转变。作为一个新的方面,本综述总结了关于雄激素和雄激素剥夺对血小板活性影响的现有数据,血小板在炎症以及动脉粥样硬化病变的发生和发展中起主要作用。睾酮可调节血小板聚集反应,这受剂量水平、雄激素来源和年龄的影响。关于ADT对血小板活性和聚集影响的数据有限且相互矛盾,因为有报道称ADT期间血小板聚集反应既有增加也有减少。ADT期间导致心血管风险增加的机制方面仍存在知识空白,有必要进一步研究。更好地理解将ADT与心血管风险联系起来的致病途径,可能有助于识别临床上有用的诊断和预后生物标志物,并加速寻找新的治疗靶点,从而优化前列腺癌的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0458/11619638/686d669c6e13/40959_2024_278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0458/11619638/7965b08750a2/40959_2024_278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0458/11619638/686d669c6e13/40959_2024_278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0458/11619638/7965b08750a2/40959_2024_278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0458/11619638/686d669c6e13/40959_2024_278_Fig2_HTML.jpg

相似文献

1
Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.血栓炎症将雄激素抑制与前列腺癌患者的心血管风险联系起来。
Cardiooncology. 2024 Dec 5;10(1):87. doi: 10.1186/s40959-024-00278-2.
2
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review.雄激素剥夺疗法对前列腺癌患者的心血管影响:一项系统评价
Cureus. 2022 Jun 22;14(6):e26209. doi: 10.7759/cureus.26209. eCollection 2022 Jun.
3
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.雄激素剥夺疗法对晚期前列腺癌患者心血管系统的影响。
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Targeting the androgen receptor signaling pathway in advanced prostate cancer.针对晚期前列腺癌的雄激素受体信号通路。
Am J Health Syst Pharm. 2022 Jul 22;79(15):1224-1235. doi: 10.1093/ajhp/zxac105.
6
Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.心血管风险和毒性 - 前列腺癌患者去势治疗的阿喀琉斯之踵。
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188383. doi: 10.1016/j.bbcan.2020.188383. Epub 2020 Jun 11.
7
Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.肥胖与雄激素剥夺治疗后行根治性前列腺切除术的男性的去势抵抗性疾病和转移相关:来自 SEARCH 数据库的结果。
BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.
8
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.与前列腺癌去势治疗相关的代谢后遗症。
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):240-6. doi: 10.1097/MED.0b013e3283391fd1.
9
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?雄激素剥夺疗法与心血管疾病:连接机制是什么?
Ther Adv Urol. 2016 Apr;8(2):118-29. doi: 10.1177/1756287215617872. Epub 2015 Nov 30.
10
Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.雄激素剥夺疗法与前列腺癌患者的抑郁:风险与药物治疗综述。
Aging Male. 2022 Dec;25(1):101-124. doi: 10.1080/13685538.2022.2053954.

引用本文的文献

1
Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.癌症中的心房颤动与缺血性卒中:最新科学证据、当前管理及未来方向
J Thromb Thrombolysis. 2025 Apr 26. doi: 10.1007/s11239-025-03104-3.

本文引用的文献

1
FSH Is Responsible for Androgen Deprivation Therapy-Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion.FSH 通过加剧血管内皮炎症和单核细胞黏附导致雄激素剥夺治疗相关的动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):698-719. doi: 10.1161/ATVBAHA.123.319426. Epub 2024 Jan 11.
2
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review.GnRH拮抗剂与激动剂对前列腺癌心血管影响的比较:一项系统评价
JACC CardioOncol. 2023 Aug 1;5(5):613-624. doi: 10.1016/j.jaccao.2023.05.011. eCollection 2023 Oct.
3
P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions.
P2Y12 抑制可抑制促炎的血小板-单核细胞相互作用。
Thromb Haemost. 2023 Feb;123(2):231-244. doi: 10.1055/s-0042-1758655. Epub 2023 Jan 11.
4
Platelet aggregation in Klinefelter syndrome is not aggravated by testosterone replacement therapy: A longitudinal follow-up study.克莱恩费尔特综合征患者的血小板聚集并未因睾丸素替代疗法而加重:一项纵向随访研究。
Andrology. 2023 Mar;11(3):456-463. doi: 10.1111/andr.13330. Epub 2022 Nov 21.
5
Platelets, a Key Cell in Inflammation and Atherosclerosis Progression.血小板:炎症和动脉粥样硬化进展中的关键细胞
Cells. 2022 Mar 17;11(6):1014. doi: 10.3390/cells11061014.
6
Neutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease.中性粒细胞与血小板的相互作用作为心血管疾病的新型治疗靶点
Front Cardiovasc Med. 2022 Jan 31;8:824112. doi: 10.3389/fcvm.2021.824112. eCollection 2021.
7
Epidemiology and Prevention of Prostate Cancer.前列腺癌的流行病学与预防。
Eur Urol Oncol. 2021 Dec;4(6):877-892. doi: 10.1016/j.euo.2021.09.006. Epub 2021 Oct 26.
8
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性:PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
9
Prostate cancer.前列腺癌。
Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6.
10
Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association.激素依赖性癌症(乳腺癌和前列腺癌)治疗中激素疗法对心血管系统的影响:作用和改变:美国心脏协会的科学声明。
Circ Genom Precis Med. 2021 Jun;14(3):e000082. doi: 10.1161/HCG.0000000000000082. Epub 2021 Apr 26.